The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Annexin A1 Counteracts Chemokine-Induced Arterial Myeloid Cell Recruitment
Open accessAbstract
Rationale: Chemokine-controlled arterial leukocyte recruitment is a crucial process in atherosclerosis. Formyl peptide receptor 2 (FPR2) is a chemoattractant receptor that recognizes proinflammatory and proresolving ligands. The contribution of FPR2 and its proresolving ligand annexin A1 to atherosclerotic lesion formation is largely undefined. Objective: Because of the ambivalence of FPR2 ligands, we here investigate the role of FPR2 and its resolving ligand annexin A1 in atherogenesis. Methods and Results: Deletion of FPR2 or its ligand annexin A1 enhances atherosclerotic lesion formation, arterial myeloid cell adhesion, and recruitment. Mechanistically, we identify annexin A1 as an endogenous inhibitor of integrin activation evoked by the chemokines CCL5, CCL2, and CXCL1. Specifically, the annexin A1 fragment Ac2-26 counteracts conformational activation and clustering of integrins on myeloid cells evoked by CCL5, CCL2, and CXCL1 through inhibiting activation of the small GTPase Rap1. In vivo administration of Ac2-26 largely diminishes arterial recruitment of myeloid cells in a FPR2-dependent fashion. This effect is also observed in the presence of selective antagonists to CCR5, CCR2, or CXCR2, whereas Ac2-26 was without effect when all 3 chemokine receptors were antagonized simultaneously. Finally, repeated treatment with Ac2-26 reduces atherosclerotic lesion sizes and lesional macrophage accumulation. Conclusions: Instructing the annexin A1-FPR2 axis harbors a novel approach to target arterial leukocyte recruitment. With the ability of Ac2-26 to counteract integrin activation exerted by various chemokines, delivery of Ac2-26 may be superior in inhibition of arterial leukocyte recruitment when compared with blocking individual chemokine receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the increased atherosclerosis burden observed in Apoe−/−Anxa1−/− mice compared with Apoe−/− mice can be reduced by treatment with the annexin A1 mimetic peptide Ac2–26, whereas this treatment does not affect atherosclerotic lesion size in Apoe−/− mice lacking ALX/FPR2 (REF108).”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Self-citationLeukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure
Świrski, F. K., & Nahrendorf, M. (2013) · Science · doi:10.1126/science.1230719 · Cited by 1,121
Resolution of inflammation: an integrated view
Ortega‐Gómez, A., Perretti, M., & Soehnlein, O. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202382 · Cited by 776
Self-citationHyperlipidemia-triggered neutrophilia promotes early atherosclerosis
Drechsler, M., Megens, R. T. A., van Zandvoort, M., Weber, C., & Soehnlein, O. (2010) · Circulation · doi:10.1161/circulationaha.110.961714 · Cited by 698
Self-citationCombadière, C., Potteaux, S., Rodero, M. P., Simon, T., Pézard, A., Esposito, B., Merval, R., Proudfoot, A. E. I., Tedgui, A., & Mallat, Z. (2008) · Circulation · doi:10.1161/circulationaha.107.745091 · Cited by 696
Kempf, T., Zarbock, A., Widera, C., Butz, S., Stadtmann, A., Rossaint, J., Bolomini-Vittori, M., Korf-Klingebiel, M., Napp, L. C., Hansen, B., et al. (2011) · Nature Medicine · doi:10.1038/nm.2354 · Cited by 518
The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
Chiang, N., Serhan, C. N., Dahlén, S., Drazen, J. M., Hay, D. W. P., Rovati, G. E., Shimizu, T., Yokomizo, T., & Brink, C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.4 · Cited by 464
MIGEOTTE, I., COMMUNI, D., & PARMENTIER, M. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.09.009 · Cited by 457
Annexin I Is an Endogenous Ligand that Mediates Apoptotic Cell Engulfment
Arur, S., Uche, U. E., Rezaul, K., Fong, M., Scranton, V., Cowan, A. E., Mohler, W., & Han, D. K. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00090-x · Cited by 434
Regulation of leukocyte recruitment by the long pentraxin PTX3
Deban, L., Russo, R. C., Sironi, M., Moalli, F., Scanziani, M., Zambelli, V., Cuccovillo, I., Bastone, A., Gobbi, M., Valentino, S., et al. (2010) · Nature Immunology · doi:10.1038/ni.1854 · Cited by 426
Cited by
Sorted by citations
Items 101–150 of 150
Pro-resolution therapeutics for cardiovascular diseases
Heinz, J., Marinello, M., & Fredman, G. (2017) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2017.03.004 · Cited by 12
Pulmonary Hypertension Remodels the Genomic Fabrics of Major Functional Pathways
Mathew, R., Huang, J. L., Iacobaş, S., & Iacobaş, D. A. (2020) · Genes · doi:10.3390/genes11020126 · Cited by 12
Annexins: Involvement in cholesterol homeostasis, inflammatory response and atherosclerosis
Méndez‐Barbero, N., Gutiérrez‐Muñoz, C., Blázquez‐Serra, R., Martı́n-Ventura, J. L., & Blanco‐Colio, L. M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.07.001 · Cited by 12
Annexin A8 deficiency delays atherosclerosis progression
Gutiérrez‐Muñoz, C., Blázquez‐Serra, R., Sebastián-Jaraba, I. S., Sanz-Andrea, S., Fernández‐Gómez, M. J., Núñez‐Moreno, G., Mínguez, P., Escolá‐Gil, J. C., Nogales, P., Ollivier, V., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70176 · Cited by 10
Basic Mechanisms of Atherosclerosis
Bäck, M., & Hansson, G. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00004-2 · Cited by 12
Proresolving Lipid Mediators Restore Balance to the Vulnerable Plaque
Thorp, E. B. (2016) · Circulation Research · doi:10.1161/circresaha.116.309794 · Cited by 10
Annexin A: Cell Death, Inflammation, and Translational Medicine
Qian, Z., Li, Z., Peng, X., Mao, Y., Mao, X., & Li, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s511439 · Cited by 10
The roles of mechanotransduction, vascular wall cells, and blood cells in atheroma induction
Novikova, O. A., Laktionov, P. P., & Karpenko, A. A. (2018) · Vascular · doi:10.1177/1708538118796063 · Cited by 9
Emerging self-assembling peptide nanomaterial for anti-cancer therapy
Zhu, L., Shi, Y., Xiong, Y., Ba, L., Li, Q., Qiu, M.-J., Zou, Z., & Peng, G. (2021) · Journal of Biomaterials Applications · doi:10.1177/08853282211027882 · Cited by 10
Novikova, O. A., Laktionov, P. P., & Karpenko, A. A. (2018) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2018.04.030 · Cited by 9
Neutrophils and periodontitis: From pathological mechanisms to therapeutic opportunities
Si, L., Li, N., & Yang, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115912 · Cited by 8
Inflammation-resolution signalling in cardiac repair, remodelling, and heart failure
Halade, G. V., Bäck, M., & Kain, V. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf157 · Cited by 9
Unleashing the power of formyl peptide receptor 2 in cardiovascular disease
Prevete, N., Poto, R., Marone, G., & Varricchi, G. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156298 · Cited by 8
Wang, T., Wang, X., Ren, W., Sun, Z., Zhang, Y., Wu, N., & Diao, H. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101332 · Cited by 7
Méndez‐Barbero, N., Gutiérrez‐Muñoz, C., Blázquez‐Serra, R., Martı́n-Ventura, J. L., & Blanco‐Colio, L. M. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.010 · Cited by 7
Huang, Y., Han, Z., Shen, T., Zheng, Y., Yang, Z., Fan, J., Wang, R., Yan, F., Tao, Z., Luo, Y., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14825 · Cited by 6
Broering, M. F., Tocci, S., Sout, N. T., Reutelingsperger, C. P. M., Farsky, S. H. P., Das, S., & Sayed, I. M. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10708-4 · Cited by 6
Novel strategies to promote resolution of inflammation to treat lower extremity artery disease
Zhang, Q., Li, F., Ritchie, R. H., Woodman, O. L., Zhou, X., & Qin, C. X. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102263 · Cited by 6
Lin, X., Zhang, H., Liu, J., Wu, C., McDavid, A., Boyce, B. F., & Xing, L. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.806528 · Cited by 6
Anghelache, M., Voicu, G., Anton, R., Safciuc, F., Boteanu, D., Deleanu, M., Turtoi, M., Simionescu, M., Mânduțeanu, I., & Călin, M. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101733 · Cited by 5
Wang, H., Li, Y., Zhang, L., Lü, M., Li, C., & Li, Y. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01285-z · Cited by 6
Decreased serum Annexin A1 levels in Kawasaki disease with coronary artery aneurysm
Weng, H., Peng, Y., Pei, Q., Jing, F., Yang, M., & Yi, Q. (2020) · Pediatric Research · doi:10.1038/s41390-020-0898-2 · Cited by 5
Ambrish, T., Jayaswamy, P. K., Haridas, V., Kellarai, A., Shetty, S., & Shetty, P. K. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104085 · Cited by 4
Boros-Rausch, A., Dorogin, A., Nadeem, L., Shynlova, O. P., & Lye, S. J. (2025) · Cells · doi:10.3390/cells14070514 · Cited by 4
Formyl peptide receptor 1 and its antagonist T0080 in atherosclerosis
Li, Y.-J., Zhao, X., Wu, S., Yao, N., Zhang, X., Liu, Y., Tian, X., Li, Y., Gao, B., Johnston, S. C., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01506-7 · Cited by 4
Annexin A1 exerts renoprotective effects in experimental crescentic glomerulonephritis
Labes, R., Dong, L., Mrowka, R., Bachmann, S., von Vietinghoff, S., & Paliege, A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.984362 · Cited by 4
He, X., Shao, G., Du, X., Hua, R., Song, H., Chen, Y., Zhu, X., & Yang, G. (2023) · Parasites & Vectors · doi:10.1186/s13071-023-05967-y · Cited by 4
Fine-tuning inflammation-resolution programs
Fredman, G., Sadhu, S., & Rymut, N. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000351 · Cited by 4
Miao, L., Wang, L., Wan, L., Xu, J., Li, Y., Cao, L., & Lin, S. (2022) · Clinical Complementary Medicine and Pharmacology · doi:10.1016/j.ccmp.2022.100049 · Cited by 4
Lack of Proteinase 3 Stabilizes Advanced Atherosclerotic Lesions
Ortega‐Gómez, A., & Soehnlein, O. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1710316 · Cited by 3
Self-citationAssociation between polymorphisms in miRNAs and ischemic stroke: A meta-analysis
Jing, Y., Hu, S., Song, J., Xu, D., Zhang, Y., Sun, X., & Wang, D. (2022) · Medicine · doi:10.1097/md.0000000000032078 · Cited by 3
Crosstalk Between Inflammatory Cells to Promote Cardioprotective Angiogenesis
Giannarelli, C., & Wong, C. K. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.014 · Cited by 3
Sajid, S., Zariwala, M. G., Mackenzie, R., Turner, M. C., Nell, T. A., Bellary, S., & Renshaw, D. W. (2022) · Nutrients · doi:10.3390/nu14112360 · Cited by 3
Formylpeptide receptors: A novel target to treat cardiometabolic complications
Leo, C. H., Vecchio, E. A., Fu, T., Yi, X., Peng, C., Zhao, P., Woodman, O. L., Baell, J. B., Ritchie, R. H., & Qin, C. X. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108941 · Cited by 2
Brianza-Padilla, M., & Bojalil, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-21735-8_5 · Cited by 2
Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy
Șuică, V. I., Uyy, E., Ivan, L., Boteanu, R. M., Cerveanu‐Hogas, A., Hansen, R., & Antohe, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911174 · Cited by 2
The Changing Face of Atherosclerosis
Meiliana, A., & Wijaya, A. (2023) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v15i3.2347 · Cited by 2
Tsai, Y.-F., Yang, S.-C., & Hwang, T. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2515882 · Cited by 2
Wickstead, E. S., Elliott, B., Biggs, C. S., Getting, S. J., & McArthur, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.09.195198 · Cited by 2
Therapeutic potential of the annexin A family in atherosclerosis
Jarad, S., & Zhang, D. (2025) · Clinical and Translational Discovery · doi:10.1002/ctd2.70064 · Cited by 1
Fei, Y., Liu, L., Hao, X., Han, Y., Luo, R., & Zhao, A. (2026) · Med-X · doi:10.1007/s44258-025-00074-2 · Cited by 1
Sosnowski, D. K., Hébert, T. E., Dobrev, D., & Nattel, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100129 · Cited by 1
Bergström, I. (2015) · Linköping University medical dissertations · doi:10.3384/diss.diva-114123 · Cited by 1
ApoE-Knockout Mice: What are New Achievements of this Model of Atherosclerosis?
Lorkowska-Zawicka, B., & Jawień, J. (2021) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2021.05.0737
Monocytes Chat With Atherosclerotic Lesions
Soehnlein, O. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308176 · Cited by 1
Self-citationThe role of FPR2/ALX in the vascular wall
Petri, M. H. (2015) · Figshare
Acquired alteration in platelets
Baaten (2018) · doi:10.26481/dis.20180315cb
Formyl-peptide receptor type 2 activation mitigates secondary organ damage in inflammatory arthritisPreprint
Margraf, A., Chen, J., Christoforou, M., Claria-Ribas, P., Schneider, A. H., Cecconello, C., Bu, W., Imbert, P. R. C., Wright, T. D., Russo, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.03.636210
Jiang, M., Sun, L., Jia, Y., Ren, X., Han, L., Zhu, Z., & Zheng, X. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.03.019
He, X., Shao, G., Du, X., Hua, R., Song, H., Chen, Y., Zhu, X.-S., & Yang, G. (2024) · Figshare · doi:10.6084/m9.figshare.26624077
Metadata
- Authors
- Drechsler, M., de Jong, R., Rossaint, J., Viola, J. R., Leoni, G., Wang, J. M., Grommes, J., Hinkel, R., Kupatt, C., Weber, C., Döring, Y., Zarbock, A., & Soehnlein, O.
- Affiliations
- National Institutes of Health (US)
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany (M.D., R.d.J., J.R.V., G.L., J.G., C.W., Y.D., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, Amsterdam, The Netherlands (M.D., O.S.); Department of Anaesthesiology, University Münster, Münster, Germany (J.R., A.Z.); Max Planck Institute, Münster, Germany (J.R., A.Z.); Laboratory of Molecular Immunoregulation, NCI, Frederick, MD (J.M.W.); European Vascular Center Aachen...
- ORCID
- Venue
- Circulation Research
- Published
- 2015-02-27
- Volume
- 116
- Issue
- 5
- Pages
- 827-835
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- PMC
- PMC7751381
- OpenAlex
- W2100320418
- Cited by
- 150
- References
- 44
- Citations by year
- 2026: 3 · 2025: 16 · 2024: 8 · 2023: 8 · 2022: 22 · 2021: 14 · 2020: 9 · 2019: 15 · 2018: 17 · 2017: 9 · 2016: 17 · 2015: 12
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Research (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010015)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
- Keywords
- annexin A1, formyl peptide receptor 2, atherosclerosis, integrin activation, Rap1, chemokines, RANTES, MCP-1, CXCL1, Ac2-26, macrophage accumulation, chemokine receptor antagonists
- MeSH terms
- Animals, Aortic Diseases, Apolipoproteins E, Chemotaxis, Dietary Fats, Mice, Inbred C57BL, Peptides, Annexin A1, Mice, Knockout, Chemokine CCL2, Chemokine CCL5, Receptors, CCR5, rap1 GTP-Binding Proteins, Myeloid Cells, Receptors, Interleukin-8B, Receptors, Formyl Peptide, Atherosclerosis, Mice, Chemokine CXCL1, Receptors, CCR2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
